(Q38765011)

6 September 2017

Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus (English)

1 reference

6 September 2017

1 reference

Jennifer N Clements

1

1 reference

PubMed ID

26953280

6 September 2017

Larkin Bello

series ordinal

2

1 reference

6 September 2017

1 March 2016

1 reference

American Journal of Health-System Pharmacy

6 September 2017

1 reference

6 September 2017

73

1 reference

6 September 2017

6

1 reference

6 September 2017

359-366

1 reference

Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy

6 September 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

AACE/ACE comprehensive diabetes management algorithm 2015.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL(-1) and Glargine 100 U mL (-1) in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month e

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

Basal insulin and cardiovascular and other outcomes in dysglycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP150174

31 March 2020

Identifiers

DOI

10.2146/AJHP150174

1 reference

6 September 2017

1 reference

PubMed ID

26953280